News headlines about MediciNova (NASDAQ:MNOV) have trended somewhat positive on Sunday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MediciNova earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.625676033089 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several equities analysts have recently issued reports on MNOV shares. BidaskClub upgraded shares of MediciNova from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. ValuEngine upgraded shares of MediciNova from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th.

MediciNova (NASDAQ MNOV) opened at $11.29 on Friday. MediciNova has a 1-year low of $4.40 and a 1-year high of $11.45. The stock has a market cap of $425.68, a P/E ratio of -35.28 and a beta of 0.18.

ILLEGAL ACTIVITY NOTICE: “MediciNova (MNOV) Receives Daily Coverage Optimism Score of 0.23” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at

About MediciNova

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Insider Buying and Selling by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with's FREE daily email newsletter.